Spiral Therapeutics Partners with VeDA to Elevate Patient Support and Research

spiral veda partnership
October 31, 2023

SAN FRANCISCO, CALIFORNIA — Spiral Therapeutics, Inc., a pioneering clinical-stage pharmaceutical company specializing in therapies for inner ear disorders, unveiled a new partnership with the Vestibular Disorders Association (VeDA) today.

This alliance aims to improve the lives of patients suffering from balance disorders like Meniere’s Disease through targeted outreach, collaborative patient education programs, and data-driven research.

“Joining forces with VeDA is a significant milestone for Spiral, as it aligns with our commitment to address the unmet medical needs in the field of inner ear disorders. We’re honored to support VeDA’s mission and excited about the opportunity to significantly improve patient lives.”

–Hugo Peris, CEO of Spiral Therapeutics

Cynthia Ryan, Executive Director of VeDA, reciprocated the sentiment, saying, “VeDA is honored to partner with Spiral in our mutual effort to support Meniere’s patients on their journey back to balance. We’re excited about the potential their new treatment offers to improve the lives of people struggling with vertigo, hearing loss, and tinnitus.”

Improving Lives of People with Balance Disorders

The partnership will empower Spiral with access to VeDA’s invaluable Patient Registry, focused on individuals coping with Meniere’s Disease, thereby enhancing their ongoing research endeavors.

Furthermore, VeDA will play a pivotal role in targeted outreach to Meniere’s clinicians and patients in both the United States and Australia. Additionally, the two organizations will collaborate on educational programs designed to enhance patient understanding of treatment nuances, including aspects such as the placebo effect.

SPT-2101: Ongoing Clinical Progress

Spiral continues to advance its inner ear programs, including its lead candidate SPT-2101 for Meniere’s Disease. The data from SPT-2101’s open label trial in Australia continues to support the safety and superior efficacy of Spiral’s proprietary drug delivery platform. Encouraged by these milestones, Spiral plans to submit an Investigational New Drug (IND) application for SPT-2101 in the United States in 2024.

**Readers interested to learn more about Spiral can check out this March 2023 interview with company CEO Hugo Peris and Chief Medical officer, Dr. Charles Limb


About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline with focus on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a long-acting steroid formulation for the treatment of inner ear inflammation. For more information, visit: www.spiraltx.com

About the Vestibular Disorders Association (VeDA)
The Vestibular Disorders Association is a global organization committed to providing support, education, and advocacy to vestibular patients and the healthcare professionals who treat them. For more information, visit: www.vestibular.org


Source: Spiral Therapeutics, VeDA

Leave a Reply